A second “bivalent” coronavirus vaccine has been approved by the UK’s health watchdog ahead of a series of booster jabs this autumn.
The regulator confirmed the Pfizer/BioNTech’s vaccine had met its standards of safety, quality and effectiveness.
The vaccine is called 'bivalent' because it targets both the original strain of coronavirus and the Omicron variant that emerged at the end of 2021, and follows a similar booster from Moderna which was approved in August.
